An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas,Expert Opinion on Biological Therapy

当前位置： X-MOL 学术 › Expert Opin. Biol. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas
Expert Opinion on Biological Therapy ( IF 4.6 ) Pub Date : 2024-02-02 , DOI: 10.1080/14712598.2024.2312243
Kamila Polgarova _{1,

2} , Marek Trneny _{1,

2}

Affiliation

Significant proportion of patients with diffuse large B-cell lymphoma (DLBCL) is refractory or relapse (R/R) after the treatment. The prognosis of this patient cohort remains poor. Novel strategies...

中文翻译：